Founded in 2011, Sophia Genetics is aiming to achieve profitability by the close of 2026. According to Jurgi Camblong,co-founder and managing director of the company,headquartered in Rolle (VD),this goal remains firm. “We aim for a profitability Ebitda [bénéfice avant intérêts,impôts,dépréciation et amortissement,ou bénéfice d’exploitation,ndlr] At the end of 2026,” he stated. “This is the indicator that counts for the markets.”

As of May 6,the company reported a 15% increase in turnover at constant exchange rates,reaching $17.8 million (14.7 million francs). However, it also recorded a net loss increase of 27% year-over-year, amounting to 17.4 million (14.4 million francs), while the loss from operations was 9.8 million, reflecting a 24% improvement compared to the previous year.

We aim for a profitability Ebitda at the end of 2026. This is the indicator that counts for the markets.

Understanding EBITDA and Profitability

EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is a key metric used to assess a company’s operating performance. sophia Genetics, a company specializing in data-driven medicine, is focusing on achieving positive EBITDA to demonstrate its financial health and appeal to investors.

Financial Performance and Future Outlook

Despite the reported increase in turnover, the rise in net losses highlights the challenges Sophia Genetics faces in achieving sustainable profitability. The company’s focus on EBITDA as a key performance indicator reflects its strategy to demonstrate underlying operational efficiency to the markets.

The biotechnology sector is known for its high research and development costs, and companies often experience losses in their early stages as they invest in innovation. Sophia genetics’ goal to become profitable by the end of 2026 will depend on its ability to manage costs,drive revenue growth,and capitalize on the expanding market for data-driven medicine.